Licensing · GCC · Announced 24 Jun 2026
Biosidus → Mubadala Bio
Licensing deal between Biosidus (Argentina) and Mubadala Bio (United Arab Emirates), covering Biosimilars, announced 24 Jun 2026. Value: Undisclosed.
Parties: BIOSIDUS S.A. (Argentina) → MUBADALA BIO (United Arab Emirates)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- United Arab Emirates, expected GCC Expansion.
- Therapeutic area
- Oncology
- Asset
- Biosimilars : epoetin alfa, filgrastim, interferon beta, and somatropin
- Announced
- 24 Jun 2026
Our analysis
🔬 The Biosimilar Fast-Track (Build vs. Buy)
Developing biologics from scratch takes over a decade and billions of dollars. By licensing BIOSIDUS 's mature, globally recognized portfolio, Mubadala Bio skips the high-risk R&D phase. This allows DiabTec to instantly establish a reliable pipeline of critical medications for oncology, nephrology, and endocrinology.
The full analysis is free to read with a work email on this page.
Source: PR Newswire